Developer docs
API playgroundTry for free, no card

Search company profiles

Calyx

Full company profile

uuid0006dpi

Namestring
Calyx
Legal namestring
Calyx Services Inc.
Websiteurl
calyx.ai
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Calyx Services Inc., now operating under the unified brand Perceptive, is a privately held clinical research services organization headquartered in Irvine, California, with 1,001–5,000 employees and a delivery footprint across the US, Europe, and Asia. The company provides medical imaging, eClinical, and regulatory solutions to global biopharmaceutical sponsors and contract research organizations, organized into three sub-brands: Perceptive Discovery (preclinical imaging, radiochemistry, biodistribution, and in-house clinical/imaging centers), Perceptive eClinical (IRT/RTSM, eCOA, and clinical intelligence), and Perceptive Imaging (clinical imaging core lab services). The product portfolio includes the proprietary VivoQuant™ preclinical imaging analysis software alongside services spanning CNS, oncology, hematology, rare diseases, radiopharmaceutical therapy, and obesity indications.

Underlying technology comprises a clinical imaging core lab platform, a randomization and trial supply management (IRT/RTSM) system, an electronic clinical outcome assessment (eCOA) capability, and a Clinical Intelligence analytics layer. The business model combines per-trial professional services contracts with subscription and licensing revenue from IRT/RTSM and eClinical software, sold primarily through enterprise field sales directly to large pharma sponsors and CROs. The organization reports having supported 11,000+ trials and 800+ regulatory approvals cumulatively across 50+ years of combined experience.

In 2024, Calyx acquired Invicro from REALM IDx, Inc. and subsequently rebranded the combined entity as Perceptive, consolidating preclinical imaging, clinical trial imaging, and RTSM services under a single global brand. The company is led by CEO Gavin Nichols alongside a full operating C-suite covering commercial, medical, digital, legal, and people functions.

Short descriptiontext

Perceptive (formerly Calyx) is a global clinical research services provider delivering medical imaging, preclinical imaging, IRT/RTSM, eCOA, and clinical intelligence solutions to biopharmaceutical sponsors and CROs across the US, Europe, and Asia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersNottingham, United Kingdom
HQ citystring
Nottingham
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
clinical trial imaging, imaging core lab, RTSM services, eCOA solutions, preclinical imaging
Industry3 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code3 codes
  • Medical Laboratories621511
  • Scientific Research and Development Services5417
  • Analytical Laboratory Instrument Manufacturing334516
SIC code3 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
  • Laboratory Analytical Instruments3826
Product category
Clinical Trial Imaging & eClinical Services
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Clinical Imaging Services
TypeProfessional Services
Description

Provides imaging core lab services for clinical trials including medical imaging acquisition, reading, and analysis across multiple therapeutic areas. Services are contracted on a per-trial basis, typically as part of larger clinical development programs with pharmaceutical sponsors.

perceptive.com
2IRT/RTSM Services
TypeSubscription Recurring
Description

Randomization and Trial Supply Management services provided as SaaS or managed service for clinical trials. Revenue generated through licensing and service fees for the IRT/RTSM platform.

perceptive.com
3Preclinical Imaging Services
TypeProfessional Services
Description

Preclinical imaging services including in-house imaging centers, radiochemistry, biodistribution services, and radioligand binding assay services for early-stage drug discovery and development.

perceptive.com
4eClinical Services
TypeSubscription Recurring
Description

Electronic clinical outcome assessment (eCOA) and related eClinical services for clinical trials.

perceptive.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Perceptive
Description

Unified brand for preclinical imaging, clinical trial imaging, and randomization and trial supply management (RTSM) services

perceptive.com
+3 more records
Core offering1 text field

Calyx (now Perceptive) provides clinical trial medical imaging core lab services, preclinical imaging, randomization and trial supply management (IRT/RTSM), electronic clinical outcome assessments (eCOA), clinical intelligence analytics, radiochemistry, biodistribution, and radioligand binding assay services to pharmaceutical sponsors and CROs. Its proprietary VivoQuant™ software supports preclinical imaging analysis. Services are delivered through direct enterprise contracts and SaaS-style platform licensing to support drug development programs across CNS, oncology, hematology, rare diseases, obesity, and radiopharmaceutical therapy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 11,000+ trials implemented
+2 more records
Product overview1 text field

Perceptive (formerly Calyx) operates as an integrated platform of clinical research services with three interconnected divisions: Discovery (preclinical imaging, radiochemistry, and in-house imaging centers), eClinical (IRT/RTSM, eCOA, and clinical intelligence), and Imaging (core lab services). The portfolio includes the VivoQuant™ software product for preclinical image analysis. With over 50 years of combined experience, the company supports 11,000+ trials and 800+ regulatory approvals across therapeutic areas including CNS, oncology, hematology, rare diseases, and radiopharmaceutical therapy.

Product and service10 records
1Imaging Core Lab
CategoryClinical Trial Imaging Services
Description

Centralized clinical trial imaging core laboratory providing standardized medical image acquisition, quality control, and analysis services for clinical studies, delivered to pharmaceutical sponsors and CROs.

2Preclinical Imaging
CategoryPreclinical Imaging Services
Description

Preclinical imaging services supporting drug discovery and development through in vivo imaging of animal models using multiple imaging modalities, targeted at pharmaceutical and biotech sponsors.

3IRT/RTSM
CategoryeClinical Services
Description

Interactive Response Technology and Randomization and Trial Supply Management services for managing patient randomization, drug allocation, and supply chain logistics in clinical trials, delivered to pharmaceutical sponsors and CROs.

4VivoQuant™
CategorySoftware Product
Description

Proprietary preclinical imaging analysis software for processing and analyzing in vivo imaging data from modalities including PET, SPECT, CT, and optical imaging, licensed to drug development teams.

5eCOA
CategoryeClinical Services
Description

Electronic Clinical Outcome Assessment services enabling electronic capture of patient-reported, clinician-reported, and observer-reported outcomes in clinical trials, delivered to pharmaceutical sponsors and CROs.

6Clinical Intelligence
CategoryAnalytics Platform
Description

Data analytics and insights platform providing clinical trial performance monitoring, operational metrics, and decision support capabilities across imaging and eClinical operations for sponsors.

7In-House Clinical and Imaging Centers
CategoryClinical Research Infrastructure
Description

Proprietary clinical and imaging center facilities enabling end-to-end study execution with integrated patient enrollment, imaging, and data collection capabilities for sponsor trials.

8Radiochemistry
CategoryDiscovery Services
Description

Radiopharmaceutical production and radiochemistry services supporting preclinical and clinical molecular imaging studies using PET and SPECT tracers for pharmaceutical and biotech sponsors.

9Biodistribution Services
CategoryDiscovery Services
Description

Quantitative analysis of radiopharmaceutical and drug distribution in tissues and organs for preclinical and clinical studies, supporting drug development programs in radiopharmaceutical therapy and theranostics.

10Radioligand Binding Assay Services
CategoryDiscovery Services
Description

Bioanalytical services for measuring radioligand binding and receptor occupancy in support of drug development programs, particularly for CNS, oncology, and rare disease therapeutics.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Medpace is a mid-to-large CRO focused on Phase II/III clinical development across multiple therapeutic areas. Comparable because it competes for the same biotech and pharma sponsors and increasingly offers imaging and eClinical capabilities.

TypeDirect peer
Description

Parexel is a global CRO offering Phase I–IV clinical development with therapeutic-area expertise. Comparable as a competing CRO serving the same enterprise pharma and biotech client base.

TypeBroad incumbent
Description

ICON is a top-tier global CRO providing Phase I–IV clinical services, including imaging and eClinical solutions. Comparable as a direct competitor for large multi-regional clinical trials where Perceptive also competes.

TypeBroad incumbent
Description

IQVIA is the largest global CRO offering full-service clinical development including imaging and RTSM. Comparable because it competes for the same pharmaceutical and biotech sponsors and can bundle Perceptive's core services into broader outsourcing contracts.

TypeDirect peer
Description

Worldwide Clinical Trials is a mid-sized global CRO focused on complex therapeutic areas including CNS, oncology, and rare diseases. Comparable as a direct competitor for the same specialty trial work that Perceptive supports.

TypeDirect peer
Description

Clario is a clinical trial technology and imaging company offering eCOA, RTSM, and medical imaging core lab services. Highly comparable because it directly overlaps with Perceptive's eClinical and imaging core lab offerings.

TypeDirect peer
Description

Charles River Laboratories provides preclinical and clinical research services, including preclinical imaging and CRO services. Comparable through its preclinical imaging and discovery services that overlap with Perceptive Discovery.

TypeEmerging player
Description

WCG provides clinical trial enablement services including site activation, IRB review, and trial technology. Comparable as an enabling peer in clinical research services that intersects with Perceptive's eClinical offerings.

TypeBroad incumbent
Description

Labcorp Drug Development is a global CRO with central laboratory, clinical development, and imaging-adjacent services. Comparable as a full-service competitor offering overlapping capabilities in clinical trial laboratory and eClinical services.

TypeEmerging player
Description

BioTel Research is a technology-enabled clinical research services provider focused on cardiac safety, imaging, and decentralized trials. Comparable as a specialized imaging and centralized diagnostic services peer overlapping with Perceptive Imaging.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Calyx

Clinical Trial Imaging & eClinical Servicescalyx.ai

Perceptive (formerly Calyx) is a global clinical research services provider delivering medical imaging, preclinical imaging, IRT/RTSM, eCOA, and clinical intelligence solutions to biopharmaceutical sponsors and CROs across the US, Europe, and Asia.

What Calyx does

Calyx Services Inc., now operating under the unified brand Perceptive, is a privately held clinical research services organization headquartered in Irvine, California, with 1,001–5,000 employees and a delivery footprint across the US, Europe, and Asia. The company provides medical imaging, eClinical, and regulatory solutions to global biopharmaceutical sponsors and contract research organizations, organized into three sub-brands: Perceptive Discovery (preclinical imaging, radiochemistry, biodistribution, and in-house clinical/imaging centers), Perceptive eClinical (IRT/RTSM, eCOA, and clinical intelligence), and Perceptive Imaging (clinical imaging core lab services). The product portfolio includes the proprietary VivoQuant™ preclinical imaging analysis software alongside services spanning CNS, oncology, hematology, rare diseases, radiopharmaceutical therapy, and obesity indications.

Underlying technology comprises a clinical imaging core lab platform, a randomization and trial supply management (IRT/RTSM) system, an electronic clinical outcome assessment (eCOA) capability, and a Clinical Intelligence analytics layer. The business model combines per-trial professional services contracts with subscription and licensing revenue from IRT/RTSM and eClinical software, sold primarily through enterprise field sales directly to large pharma sponsors and CROs. The organization reports having supported 11,000+ trials and 800+ regulatory approvals cumulatively across 50+ years of combined experience.

In 2024, Calyx acquired Invicro from REALM IDx, Inc. and subsequently rebranded the combined entity as Perceptive, consolidating preclinical imaging, clinical trial imaging, and RTSM services under a single global brand. The company is led by CEO Gavin Nichols alongside a full operating C-suite covering commercial, medical, digital, legal, and people functions.

Calyx firmographics

Firmographics
Name
Calyx
Legal name
Calyx Services Inc.
Website
https://calyx.ai
Company type
Private
Operating status
Operating
Headcount range
251–500 employees
Short description
Perceptive (formerly Calyx) is a global clinical research services provider delivering medical imaging, preclinical imaging, IRT/RTSM, eCOA, and clinical intelligence solutions to biopharmaceutical sponsors and CROs across the US, Europe, and Asia.
Ownership category
akta.pro rank

Calyx industry classification

Industry
Product category
Clinical Trial Imaging & eClinical Services
NAICS
Medical Laboratories (621511), Scientific Research and Development Services (5417), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Clinical trial imaging
  • Imaging core lab
  • RTSM services
  • ECOA solutions
  • Preclinical imaging

Where Calyx is headquartered

Location

Headquarters

HQ city
Nottingham
HQ country
United Kingdom
HQ region
Europe

Markets served

Calyx business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Clinical Imaging Services: Provides imaging core lab services for clinical trials including medical imaging acquisition, reading, and analysis across multiple therapeutic areas. Services are contracted on a per-trial basis, typically as part of larger clinical development programs with pharmaceutical sponsors.
  2. IRT/RTSM Services: Randomization and Trial Supply Management services provided as SaaS or managed service for clinical trials. Revenue generated through licensing and service fees for the IRT/RTSM platform.
  3. Preclinical Imaging Services: Preclinical imaging services including in-house imaging centers, radiochemistry, biodistribution services, and radioligand binding assay services for early-stage drug discovery and development.
  4. eClinical Services: Electronic clinical outcome assessment (eCOA) and related eClinical services for clinical trials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Calyx product offering

Product offering

Core offering

Calyx (now Perceptive) provides clinical trial medical imaging core lab services, preclinical imaging, randomization and trial supply management (IRT/RTSM), electronic clinical outcome assessments (eCOA), clinical intelligence analytics, radiochemistry, biodistribution, and radioligand binding assay services to pharmaceutical sponsors and CROs. Its proprietary VivoQuant™ software supports preclinical imaging analysis. Services are delivered through direct enterprise contracts and SaaS-style platform licensing to support drug development programs across CNS, oncology, hematology, rare diseases, obesity, and radiopharmaceutical therapy.

Product overview

Perceptive (formerly Calyx) operates as an integrated platform of clinical research services with three interconnected divisions: Discovery (preclinical imaging, radiochemistry, and in-house imaging centers), eClinical (IRT/RTSM, eCOA, and clinical intelligence), and Imaging (core lab services). The portfolio includes the VivoQuant™ software product for preclinical image analysis. With over 50 years of combined experience, the company supports 11,000+ trials and 800+ regulatory approvals across therapeutic areas including CNS, oncology, hematology, rare diseases, and radiopharmaceutical therapy.

Differentiator

Problem solved

Functional benefit

Brands

  • Perceptive: Unified brand for preclinical imaging, clinical trial imaging, and randomization and trial supply management (RTSM) services
  • Perceptive Discovery
  • Perceptive eClinical
  • Perceptive Imaging

Products and services

  • Imaging Core Lab Centralized clinical trial imaging core laboratory providing standardized medical image acquisition, quality control, and analysis services for clinical studies, delivered to pharmaceutical sponsors and CROs.
  • Preclinical Imaging Preclinical imaging services supporting drug discovery and development through in vivo imaging of animal models using multiple imaging modalities, targeted at pharmaceutical and biotech sponsors.
  • IRT/RTSM Interactive Response Technology and Randomization and Trial Supply Management services for managing patient randomization, drug allocation, and supply chain logistics in clinical trials, delivered to pharmaceutical sponsors and CROs.
  • VivoQuant™ Proprietary preclinical imaging analysis software for processing and analyzing in vivo imaging data from modalities including PET, SPECT, CT, and optical imaging, licensed to drug development teams.
  • eCOA Electronic Clinical Outcome Assessment services enabling electronic capture of patient-reported, clinician-reported, and observer-reported outcomes in clinical trials, delivered to pharmaceutical sponsors and CROs.
  • Clinical Intelligence Data analytics and insights platform providing clinical trial performance monitoring, operational metrics, and decision support capabilities across imaging and eClinical operations for sponsors.
  • In-House Clinical and Imaging Centers Proprietary clinical and imaging center facilities enabling end-to-end study execution with integrated patient enrollment, imaging, and data collection capabilities for sponsor trials.
  • Radiochemistry Radiopharmaceutical production and radiochemistry services supporting preclinical and clinical molecular imaging studies using PET and SPECT tracers for pharmaceutical and biotech sponsors.
  • Biodistribution Services Quantitative analysis of radiopharmaceutical and drug distribution in tissues and organs for preclinical and clinical studies, supporting drug development programs in radiopharmaceutical therapy and theranostics.
  • Radioligand Binding Assay Services Bioanalytical services for measuring radioligand binding and receptor occupancy in support of drug development programs, particularly for CNS, oncology, and rare disease therapeutics.

Quantifiable outcome

  • 11,000+ trials implemented
  • +2 more outcomes

Companies that use Calyx

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Calyx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Calyx partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Calyx competitors and assessment

Company assessment

Direct peers

  • Medpace: Medpace is a mid-to-large CRO focused on Phase II/III clinical development across multiple therapeutic areas. Comparable because it competes for the same biotech and pharma sponsors and increasingly offers imaging and eClinical capabilities.
  • Parexel: Parexel is a global CRO offering Phase I–IV clinical development with therapeutic-area expertise. Comparable as a competing CRO serving the same enterprise pharma and biotech client base.
  • Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized global CRO focused on complex therapeutic areas including CNS, oncology, and rare diseases. Comparable as a direct competitor for the same specialty trial work that Perceptive supports.
  • Clario: Clario is a clinical trial technology and imaging company offering eCOA, RTSM, and medical imaging core lab services. Highly comparable because it directly overlaps with Perceptive's eClinical and imaging core lab offerings.
  • Charles River Laboratories: Charles River Laboratories provides preclinical and clinical research services, including preclinical imaging and CRO services. Comparable through its preclinical imaging and discovery services that overlap with Perceptive Discovery.

Broad incumbents

  • ICON plc: ICON is a top-tier global CRO providing Phase I–IV clinical services, including imaging and eClinical solutions. Comparable as a direct competitor for large multi-regional clinical trials where Perceptive also competes.
  • IQVIA: IQVIA is the largest global CRO offering full-service clinical development including imaging and RTSM. Comparable because it competes for the same pharmaceutical and biotech sponsors and can bundle Perceptive's core services into broader outsourcing contracts.
  • Labcorp Drug Development (formerly Covance): Labcorp Drug Development is a global CRO with central laboratory, clinical development, and imaging-adjacent services. Comparable as a full-service competitor offering overlapping capabilities in clinical trial laboratory and eClinical services.

Emerging players

  • WCG (WIRB-Copernicus Group): WCG provides clinical trial enablement services including site activation, IRB review, and trial technology. Comparable as an enabling peer in clinical research services that intersects with Perceptive's eClinical offerings.
  • BioTel Research (formerly Biotelemetry/CardioNet): BioTel Research is a technology-enabled clinical research services provider focused on cardiac safety, imaging, and decentralized trials. Comparable as a specialized imaging and centralized diagnostic services peer overlapping with Perceptive Imaging.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Calyx social profiles

Digital presence

Calyx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Calyx leadership team

Management profile

Number of profiles

Profiles8 records

Calyx funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Calyx M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Calyx

What does Calyx do?

Calyx (now Perceptive) provides clinical trial medical imaging core lab services, preclinical imaging, randomization and trial supply management (IRT/RTSM), electronic clinical outcome assessments (eCOA), clinical intelligence analytics, radiochemistry, biodistribution, and radioligand binding assay services to pharmaceutical sponsors and CROs. Its proprietary VivoQuant™ software supports preclinical imaging analysis. Services are delivered through direct enterprise contracts and SaaS-style platform licensing to support drug development programs across CNS, oncology, hematology, rare diseases, obesity, and radiopharmaceutical therapy.

Is Calyx a public or private company?

Calyx is a private company. It is classified as unknown and is currently operating.

When was Calyx founded?

Calyx was founded in -1. It employs 251 to 500 people.

Where is Calyx based?

Calyx is headquartered in Nottingham, United Kingdom, in the Europe region.

How does Calyx make money?

Four revenue lines are on record. Clinical Imaging Services are the primary driver. The others are IRT/RTSM Services, preclinical Imaging Services and eClinical Services.

Who are Calyx's main competitors?

Direct peers on record are Medpace, Parexel, Worldwide Clinical Trials, Clario and Charles River Laboratories. Broad incumbents are ICON plc, IQVIA and Labcorp Drug Development (formerly Covance). Emerging players are WCG (WIRB-Copernicus Group) and BioTel Research (formerly Biotelemetry/CardioNet).

Does Calyx have an API?

No public API is recorded for Calyx.

What industry is Calyx in?

Calyx's product category is Clinical Trial Imaging & eClinical Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comRegulatory Information Management Market Outlook 2025-2035: Powered by MasterControl, Ennov, Amplexor Life Sciences, Calyx, AmpleLogic, PhlexGlobal, ArisGlobal, and Körber AGThe global regulatory information management market is projected to grow from $2.39 billion in 2025 to $6.79 billion by 2035, a CAGR of 11.0%. The U.S. leads with $1.92 billion by 2035, while India is the fastest-growing at 12.8% CAGR. Growth is driven by regulatory scrutiny, digital compliance, and AI-driven tools.PR NewswireCalyx / Invicro Forges a Strategic Collaboration with BAMF Health to Accelerate Clinical Translation of Radioligand Therapies and Immuno-Oncology AgentsCalyx/Invicro and BAMF Health announced a strategic partnership to accelerate clinical translation of radioligand therapies and immuno-oncology agents. The collaboration combines Calyx's radiochemistry and imaging with BAMF's radiopharmacy facility, targeting a catalyzing actinium-225 initiative. The partnership aims to streamline operations and speed up development for oncology treatments.PR NewswireCalyx / Invicro Forges a Strategic Collaboration with BAMF Health to Accelerate Clinical Translation of Radioligand Therapies and Immuno-Oncology AgentsCalyx/Invicro and BAMF Health announced a strategic partnership to accelerate clinical translation of radioligand therapies and immuno-oncology agents. The collaboration combines Calyx/Invicro's radiochemistry and imaging with BAMF's GE HealthCare StarGuide SPECT/CT and dosimetry expertise, targeting a catalyzing actinium-225 initiative with TerraPower.PR NewswireCalyx Medical Imaging Supports Groundbreaking Melanoma Treatment ApprovalCalyx Medical Imaging announced its role in supporting the FDA's approval of Iovance Biotherapeutics' AMTAGVI (lifileucel) for treating unresectable or metastatic melanoma, making it the first cell therapy approved to treat solid tumors. Calyx designed and implemented the imaging components of the accelerated Phase II clinical trial across 60 investigative sites, enabling uniform and consistent evaluation through its independent readers. The CEO expressed commitment to continuing collaboration with Iovance as this milestone represents a significant advancement for melanoma patients and the broader oncology research community.PR NewswireCalyx Medical Imaging Supports Groundbreaking Melanoma Treatment ApprovalCalyx Medical Imaging supported the FDA approval of Iovance's AMTAGVI, a cell therapy for melanoma, by providing imaging services for the pivotal trial. The company enabled 60 sites to capture patient images via CT, MRI, PET, and skin photography, and designed an image review methodology for consistent evaluation.PR NewswireCalyx and Invicro agree to combine to create a global leader in medical imaging and software solutions for the clinical research communityCalyx agreed to acquire Invicro from REALM IDx, creating a global medical imaging and software leader. The deal, expected in Q2 2024, will employ about 2,000 people and support nearly 12,000 clinical trials. Integration will begin after closing.PR NewswireCalyx and Invicro agree to combine to create a global leader in medical imaging and software solutions for the clinical research communityCalyx and Invicro agreed to combine, with Invicro being acquired 100% by Calyx from REALM IDx. The deal is expected to close in Q2 2024, creating a group of about 2,000 employees supporting nearly 12,000 trials.InvicroCalyx and Invicro Combine to Lead Medical ImagingCalyx has agreed to acquire 100% of Invicro from its current owner, REALM IDx, Inc., in a strategic combination expected to close in Q2 2024. The merger creates a new global leader in medical imaging and clinical research services, combining approximately 2,000 employees across the US, Europe, and Asia.PR NewswireCalyx CTMS Select Delivers Robust Functionality for Small/Mid-sized Biopharma and CROsCalyx announced CTMS Select, a pre-configured clinical trial management system for small and mid-sized biopharma and CROs. The scalable, validated solution can be implemented in 6-8 weeks and includes eTMF and EDC integrations. It is designed to lower costs compared to comparable solutions.